SG11201700706WA - Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use - Google Patents
Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of useInfo
- Publication number
- SG11201700706WA SG11201700706WA SG11201700706WA SG11201700706WA SG11201700706WA SG 11201700706W A SG11201700706W A SG 11201700706WA SG 11201700706W A SG11201700706W A SG 11201700706WA SG 11201700706W A SG11201700706W A SG 11201700706WA SG 11201700706W A SG11201700706W A SG 11201700706WA
- Authority
- SG
- Singapore
- Prior art keywords
- interleukin
- methods
- fusion proteins
- receptor alpha
- alpha fusion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033726P | 2014-08-06 | 2014-08-06 | |
| PCT/US2015/043792 WO2016022671A1 (en) | 2014-08-06 | 2015-08-05 | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201700706WA true SG11201700706WA (en) | 2017-02-27 |
Family
ID=53836871
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700706WA SG11201700706WA (en) | 2014-08-06 | 2015-08-05 | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
| SG10201913695PA SG10201913695PA (en) | 2014-08-06 | 2015-08-05 | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913695PA SG10201913695PA (en) | 2014-08-06 | 2015-08-05 | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US12084483B2 (ru) |
| EP (2) | EP3177307B1 (ru) |
| JP (3) | JP6723982B2 (ru) |
| KR (1) | KR102653758B1 (ru) |
| CN (2) | CN113912737A (ru) |
| AU (3) | AU2015301071C1 (ru) |
| BR (1) | BR112017001940A2 (ru) |
| CA (1) | CA2957273C (ru) |
| CL (1) | CL2017000284A1 (ru) |
| CO (1) | CO2017002166A2 (ru) |
| DK (1) | DK3177307T3 (ru) |
| EA (2) | EA202091342A3 (ru) |
| FI (1) | FI3177307T3 (ru) |
| IL (2) | IL250007B (ru) |
| LT (1) | LT3177307T (ru) |
| MA (2) | MA40094B1 (ru) |
| MX (1) | MX2017001062A (ru) |
| MY (1) | MY180831A (ru) |
| NZ (2) | NZ766851A (ru) |
| PE (1) | PE20170503A1 (ru) |
| PH (1) | PH12017500042A1 (ru) |
| PT (1) | PT3177307T (ru) |
| SA (1) | SA517380842B1 (ru) |
| SG (2) | SG11201700706WA (ru) |
| SI (1) | SI3177307T1 (ru) |
| TN (1) | TN2017000020A1 (ru) |
| WO (1) | WO2016022671A1 (ru) |
| ZA (1) | ZA201700245B (ru) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| EA034350B1 (ru) | 2014-02-06 | 2020-01-30 | Ф.Хоффманн-Ля Рош Аг | Слитые белки, содержащие интерлейкин-2, и их применения |
| MA40094B1 (fr) * | 2014-08-06 | 2022-05-31 | Univ Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
| US20200316118A1 (en) * | 2016-05-19 | 2020-10-08 | The General Hospital Corporation | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
| KR20190057113A (ko) | 2016-09-28 | 2019-05-27 | 조마 (유에스) 엘엘씨 | 인터루킨-2에 결합하는 항체 및 그 용도 |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| BR112019024127A2 (pt) | 2017-05-24 | 2020-06-23 | Pandion Therapeutics, Inc. | Imunotolerância alvejada |
| EP3746103A4 (en) * | 2017-12-06 | 2022-03-30 | The Board of Trustees of the Leland Stanford Junior University | PROTEINS ENGINEERED TO INCREASE A CELL'S SENSITIVITY TO IL-2 |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US20210015864A1 (en) * | 2018-03-23 | 2021-01-21 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| CN112154153A (zh) * | 2018-03-28 | 2020-12-29 | 百时美施贵宝公司 | 白介素-2/白介素-2受体α融合蛋白以及使用方法 |
| JP2022525921A (ja) * | 2019-03-18 | 2022-05-20 | バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー | 免疫エフェクタ細胞の特異的活性化のためのインターロイキン２受容体（ｉｌ２ｒ）およびインターロイキン２（ｉｌ２）バリアント |
| CN111944036B (zh) | 2019-05-14 | 2024-09-06 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | ANTI-MADCAM IMMUNE TOLERANCE |
| KR20220012256A (ko) * | 2019-05-24 | 2022-02-03 | 프로비바 테라퓨틱스 (홍콩) 리미티드 | Il-2 조성물 및 이의 사용 방법 |
| US20210038684A1 (en) * | 2019-06-11 | 2021-02-11 | Alkermes Pharma Ireland Limited | Compositions and Methods for Cancer Immunotherapy |
| CN114466657A (zh) * | 2019-07-25 | 2022-05-10 | 芝加哥大学 | 包括蛋白酶激活治疗剂的组合物和方法 |
| WO2021055568A1 (en) * | 2019-09-19 | 2021-03-25 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
| JP2022553234A (ja) * | 2019-10-18 | 2022-12-22 | アルカームス ファーマ アイルランド リミテッド | 免疫チェックポイント阻害剤と組み合わせた免疫調節ｉｌ－２剤 |
| EP4077397A2 (en) | 2019-12-20 | 2022-10-26 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| WO2021222762A2 (en) | 2020-04-30 | 2021-11-04 | Aetio Biotherapy, Inc. | Activatable il2 composition and methods of use |
| TW202317623A (zh) * | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| IL314734A (en) * | 2022-02-11 | 2024-10-01 | Mural Oncology Inc | Compositions and methods for cancer immunotherapy |
| WO2023159135A2 (en) * | 2022-02-16 | 2023-08-24 | University Of Miami | Il-2 and tl1a fusion proteins and methods of use thereof |
| CN114875069B (zh) * | 2022-04-22 | 2023-09-15 | 四川大学 | 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途 |
| WO2024175020A1 (en) * | 2023-02-22 | 2024-08-29 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-il2ra antibodies and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| FR2619719B1 (fr) | 1987-09-01 | 1991-05-10 | Sanofi Sa | Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices |
| US5250296A (en) * | 1990-11-29 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| AU704829B2 (en) | 1994-12-28 | 1999-05-06 | University Of Kentucky | Murine anti-idiotype antibody 3H1 |
| US6967092B1 (en) * | 1996-10-25 | 2005-11-22 | Mc Kearn John P | Multi-functional chimeric hematopoietic receptor agonists |
| DE19701141C1 (de) * | 1997-01-16 | 1998-04-09 | Hoechst Ag | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| KR20040040475A (ko) | 2001-09-28 | 2004-05-12 | 가부시키가이샤 디나벡크 겐큐쇼 | 에피토프 결합 β２ｍ을 코드하는 포유동물 세포감염성 바이러스 벡터 및 그의 이용 |
| AU2005227263A1 (en) | 2004-03-05 | 2005-10-06 | Novartis Vaccines And Diagnostics, Inc. | In vitro test system for predicting patient tolerability of therapeutic agents |
| NZ581779A (en) | 2005-05-17 | 2011-09-30 | Univ Connecticut | Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex |
| CN101255197B (zh) * | 2008-03-28 | 2012-01-25 | 浙江海正药业股份有限公司 | 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用 |
| GB0815216D0 (en) | 2008-08-21 | 2008-09-24 | Asterion Ltd | Interleukin |
| WO2011123683A2 (en) * | 2010-04-02 | 2011-10-06 | University Of Rochester | Protease activated cytokines |
| WO2012088383A2 (en) | 2010-12-23 | 2012-06-28 | Genentech, Inc. | PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME |
| JP6234446B2 (ja) * | 2012-06-08 | 2017-11-22 | アルカーメス，インコーポレイテッド | ムチンドメインポリペプチドに連結された活性タンパク質を含む融合ポリペプチド |
| US20140044675A1 (en) * | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| WO2014100913A1 (en) | 2012-12-24 | 2014-07-03 | Beijing Anxinhuaide Biotech. Co., Ltd | Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer |
| MA40094B1 (fr) | 2014-08-06 | 2022-05-31 | Univ Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
-
2015
- 2015-08-04 MA MA40094A patent/MA40094B1/fr unknown
- 2015-08-04 MA MA040721A patent/MA40721A/fr unknown
- 2015-08-05 EA EA202091342A patent/EA202091342A3/ru unknown
- 2015-08-05 NZ NZ766851A patent/NZ766851A/en unknown
- 2015-08-05 WO PCT/US2015/043792 patent/WO2016022671A1/en active Application Filing
- 2015-08-05 MX MX2017001062A patent/MX2017001062A/es unknown
- 2015-08-05 MY MYPI2017700387A patent/MY180831A/en unknown
- 2015-08-05 CA CA2957273A patent/CA2957273C/en active Active
- 2015-08-05 LT LTEPPCT/US2015/043792T patent/LT3177307T/lt unknown
- 2015-08-05 EA EA201790063A patent/EA035956B1/ru not_active IP Right Cessation
- 2015-08-05 NZ NZ728042A patent/NZ728042A/en unknown
- 2015-08-05 CN CN202110539190.4A patent/CN113912737A/zh active Pending
- 2015-08-05 EP EP15750560.3A patent/EP3177307B1/en active Active
- 2015-08-05 SG SG11201700706WA patent/SG11201700706WA/en unknown
- 2015-08-05 SI SI201532026T patent/SI3177307T1/sl unknown
- 2015-08-05 KR KR1020177005686A patent/KR102653758B1/ko active IP Right Grant
- 2015-08-05 AU AU2015301071A patent/AU2015301071C1/en active Active
- 2015-08-05 DK DK15750560.3T patent/DK3177307T3/da active
- 2015-08-05 JP JP2017506395A patent/JP6723982B2/ja active Active
- 2015-08-05 PE PE2017000128A patent/PE20170503A1/es unknown
- 2015-08-05 BR BR112017001940A patent/BR112017001940A2/pt active Search and Examination
- 2015-08-05 EP EP24181690.9A patent/EP4438621A2/en active Pending
- 2015-08-05 SG SG10201913695PA patent/SG10201913695PA/en unknown
- 2015-08-05 PT PT157505603T patent/PT3177307T/pt unknown
- 2015-08-05 FI FIEP15750560.3T patent/FI3177307T3/fi active
- 2015-08-05 US US15/501,392 patent/US12084483B2/en active Active
- 2015-08-05 TN TN2017000020A patent/TN2017000020A1/en unknown
- 2015-08-05 CN CN201580042330.XA patent/CN107074967B/zh active Active
-
2017
- 2017-01-06 PH PH12017500042A patent/PH12017500042A1/en unknown
- 2017-01-09 IL IL250007A patent/IL250007B/en active IP Right Grant
- 2017-01-11 ZA ZA2017/00245A patent/ZA201700245B/en unknown
- 2017-02-03 CL CL2017000284A patent/CL2017000284A1/es unknown
- 2017-02-05 SA SA517380842A patent/SA517380842B1/ar unknown
- 2017-03-03 CO CONC2017/0002166A patent/CO2017002166A2/es unknown
-
2020
- 2020-05-22 AU AU2020203352A patent/AU2020203352B2/en active Active
- 2020-06-24 JP JP2020108721A patent/JP7272663B2/ja active Active
- 2020-07-09 IL IL275944A patent/IL275944B/en unknown
-
2022
- 2022-06-10 AU AU2022204034A patent/AU2022204034A1/en not_active Abandoned
- 2022-08-25 US US17/822,333 patent/US20230079120A1/en active Pending
-
2023
- 2023-04-20 JP JP2023069282A patent/JP2023099045A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275944B (en) | Fusion protein of interleukin-2 and receptor for interleukin-2 alpha and methods of use | |
| HRP20190028T1 (hr) | Interleukin-2 fuzijski proteini i njihove primjene | |
| IL304178A (en) | Anti-gitr antibodies and methods of using them | |
| IL279606A (en) | Anti-TREM2 antibodies and methods of using them | |
| HK1243102A1 (zh) | 抗cd79b抗體和使用方法 | |
| HUE047784T2 (hu) | Anti-TIM3 antitestek és alkalmazási eljárások | |
| GB201509062D0 (en) | OX40L fusion proteins and uses thereof | |
| IL262727A (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| IL246736A0 (en) | Anti-jagged1 antibodies and methods of use | |
| IL251165A0 (en) | Anti-il-1beta antibodies and methods of their use | |
| EP3092248A4 (en) | Fusion polypeptides and methods of use | |
| HK1244534A1 (zh) | 重組疏螺旋體蛋白及其使用方法 | |
| EP3164419C0 (en) | ANTI-BRDU ANTIBODIES AND METHODS OF USE | |
| EP3322736A4 (en) | FUSION POLYPEPTIDES AND METHOD OF USE |